This handout is for nstemi in heart-transplant recipient — cardiac allograft vasculopathy (cav)-driven. Your care team identified this based on: unexplained hstn rise/fall + ecg changes in heart-transplant recipient — nstemi-equivalent in denervated graft (silent ischemia rule); cav-driven on differential.
Other reasons your team may use this plan: heart-transplant recipient (denervated graft) with new dyspnea / fatigue / hypotension / syncope + non-st-elevation ecg changes + troponin rise — silent ischemia pattern (no classic angina); known cav ishlt grade 2-3 + new lv dysfunction on echo + troponin rise → emergent angiography for cav-driven nstemi assessment with ivus; heart-transplant recipient with precipitant (anemia, sepsis, hypoxia, tachycardia, dehydration) + troponin rise + ecg changes → cav substrate + supply-demand mismatch nstemi.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| aspirin | 162-325 mg load → 81 mg | PO chewed | load once → 81 mg daily indefinitely | Universal NSTEMI — ACC/AHA 2025 Class I; same as parent cardio.nstemi.core.v1; no CNI interaction |
| ticagrelor | 180 mg load → 90 mg BID | PO | BID × 12 mo | PLATO PMID 19717846; ACC/AHA 2025 Class I; minor CYP3A4 interaction with CNI but tolerated; clopidogrel acceptable alternative if drug-drug concerns |
| clopidogrel | 300-600 mg load → 75 mg daily | PO | daily × 12 mo | Lower bleeding risk than ticagrelor; CYP-neutral with CNI; preferred when ticagrelor not tolerated or bleeding risk dominates |
| unfractionated heparin | 70-100 U/kg bolus → infusion to ACT 250-300 during PCI | IV | continuous, ACT-guided | ACC/AHA 2025 Class I parenteral AC; reversible; renal-friendly; preferred over enoxaparin in transplant given CNI nephrotoxicity baseline |
| pravastatin | 40-80 mg | PO | daily | ISHLT 2023 Class I + Kobashigawa NEJM 1995 PMID 7637810 — pravastatin is CYP3A4-neutral so does not interact with calcineurin inhibitors; standard transplant statin; AVOID simvastatin/lovastatin (CYP3A4 metabolised — toxic levels with CNI) |
| pitavastatin | 2-4 mg | PO | daily | CYP-neutral high-intensity statin alternative; ISHLT 2023 acceptable; consider if pravastatin insufficient for LDL target <70 (or <55 very-high-risk) |
| methylprednisolone | 1000 mg IV daily × 3 d (pulse therapy) | IV | daily × 3 | ISHLT 2010 (Stewart PMID 21177015) — pulse steroids first line for ≥2R ACR; also adjunct in AMR; for NSTEMI patients with concurrent rejection on biopsy |
| tacrolimus | Maintain trough 5-10 ng/mL late post-transplant; AVOID over-reduction | PO | BID | KDIGO transplant 2009 — narrow therapeutic window; sub-therapeutic trough is a modifiable rejection driver and may compound CAV-driven NSTEMI substrate; coordinate with transplant team |
| sirolimus | Trough 4-8 ng/mL with CNI reduction | PO | daily | CAVS-1 / CRAD trial + ISHLT 2024 update — mTOR inhibitor switch (with CNI reduction) slows CAV progression; strongly consider after NSTEMI in transplant recipient with confirmed CAV substrate; NOT acute therapy — chronic management decision |
| everolimus | Trough 3-8 ng/mL with CNI reduction | PO | BID | mTOR alternative to sirolimus; ISHLT 2024 update; less wound-healing impact; consider when sirolimus poorly tolerated |
| carvedilol | 3.125 mg BID titrate | PO | BID | Standard post-MI BB per ACC/AHA 2025; denervated graft adrenergic response uncertain but BB still reasonable for HFrEF; CAPRICORN PMID 11356436 historical context |
| amlodipine | 5 mg PO daily titrate | PO | daily | Preferred CCB in transplant recipients (avoid diltiazem/verapamil — CYP3A4 inhibition raises CNI levels); close CNI monitoring during titration |
| sulfamethoxazole-trimethoprim | 1 SS PO daily or 1 DS MWF (continue lifelong post-transplant) | PO | daily/MWF | PJP prophylaxis lifelong post-transplant per ISHLT 2023; verify continuity during NSTEMI hospitalization |
| valganciclovir | 900 mg PO BID × 21 d induction (renal-adjusted), then 900 mg daily × 3 mo | PO | BID induction → daily maintenance | CMV viremia accelerates CAV per Hosenpud Lancet 1998 + Valantine 2004; preemptive treatment in transplant recipient with active viremia + new CAV/NSTEMI substrate |
Plan: NSTEMI in heart-transplant recipient — CAV-aware ACS bundle; CYP3A4-safe statin selection; NSAID absolute avoidance; cautious CCB (CNI interactions); mTOR substitution for long-term CAV progression — ISHLT 2010/2023 + Kobashigawa NEJM 1995 PMID 7637810 + CAVS-1/CRAD + ACC/AHA 2025 ACS (Rao)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Transplant cardiology long-term: annual angio + IVUS for CAV; surveillance biopsy per program (decreasing frequency over time); DSA q3-6 mo; mTOR inhibitor (sirolimus / everolimus) substitution for CNI to slow CAV progression per CAVS-1 / CRAD + ISHLT 2024 update strongly considered; CYP3A4-safe statin maintenance (pravastatin/pitavastatin); cardiac rehab phase II per ACC/AHA 2025 (modified intensity); re-transplant listing if CAV ISHLT 3 with non-recoverable graft per ISHLT 2023; vaccination (NO live vaccines); cancer surveillance (skin, PTLD)
Guideline: ISHLT 2010 ACR grading + ISHLT 2013 AMR working formulation + ISHLT 2023 update + 2025 ACC/AHA ACS Guideline (Rao) + KDIGO transplant 2009 + ISHLT 2024 mTOR substitution update